Aerie Pharmaceuticals (AERI) 10-Q2018 Q1 Quarterly report

Filed: 9 May 18, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accomplished, aforementioned, aimed, analog, ATM, automatic, began, behalf, Bulletin, care, category, choice, de, dermatology, drain, EMA, enable, enacted, enactment, endothelial, entry, factor, FIFO, fluid, formulary, grow, health, healthy, humor, IND, ingredient, inhibitor, insurance, insured, internationally, IQVIA, legislation, library, line, located, MAA, maintenance, marked, Medicare, MOA, national, order, partner, payer, preliminary, prepaid, pulmonary, quality, removed, responsible, retirement, ROCK, SAB, scheduled, secondary, short, suspend, thousand, twelve, unlimited, unregistered, uveoscleral

Removed: accrual, advancement, advantage, advisory, analogue, approximate, arrangement, asleep, assigned, attestation, BCF, Bedminster, bifurcated, bifurcation, billion, California, capability, capture, Carlo, cease, component, confirmed, conjunctival, consistently, continued, decreased, delivering, deposit, differentiating, diurnal, Dublin, duration, emerging, ending, exceeded, exemption, existed, expand, expiration, feature, firm, formulation, fourth, front, highest, holder, hyperemia, identification, impairment, incidence, independent, initiate, inspection, internally, IPO, irrevocably, Irvine, iv, Jersey, Jumpstart, lack, lead, listed, long, lowering, mild, Monte, neovascularization, night, nocturnal, observed, office, payor, pilot, pivotal, placebo, placement, preparatory, prepare, preparing, project, promising, range, recoverable, recovery, reduced, resolved, resubmitted, retained, reviewed, revised, RhopressaTM, RSA, scenario, separately, significantly, simulation, specific, spectrum, spent, spread, structure, study, supportive, synergistic, term, tissue, transferred, typically, unallocated, Unamortized, vacation, volatility, withdrawn

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated AERI transcripts

AERI similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the filing of the Quarterly Report on Form 10-Q of Aerie Pharmaceuticals, Inc., a Delaware corporation (the “Company”), for the period ended March 31, 2018 (the “Report”), the undersigned, Richard J. Rubino, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:


(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and


(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.




Date: May 9, 2018				/s/ RICHARD J. RUBINO
				Richard J. Rubino
				Chief Financial Officer
				(Principal Financial and Accounting Officer)